The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs

Mara Ann McAdams Demarco, Judy A. Staffa, Gerald J. Dal Pan

Research output: Contribution to journalArticle

Abstract

Background: Ethinyl estradiol 0.03 mg/drospirenone 3 mg (EE/DRSP) contains a progestin drospirenone with antimineralocorticoid properties that may cause potassium retention leading to hyperkalemia. We estimated the percentage of EE/DRSP users prescribed concomitant potassium-sparing drugs [nonsteroidal antiinflammatory drugs, diuretics, angiotensin-converting enzyme inhibitors (with diuretics), angiotensin II agonists (with diuretics), and potassium chloride] between January 1, 2002, and March 31, 2005. Study Design: We analyzed a population-based data set of 62,527 EE/DRSP users (Dimension Rx™, Caremark). We compared the fill date and end date for each prescription (Rx) for an interacting drug to the start and end date for each EE/DRSP episode (linked Rxs). If a day of an interacting Rx overlapped with an EE/DRSP episode, concomitant prescribing was recorded. Results: A total of 17.6% of the women concomitantly used EE/DRSP and an interacting drug. Twenty-nine percent of concomitant use occurred within a month of EE/DRSP initiation. Nonsteroidal antiinflammatory drugs and diuretics were most frequently used concomitantly with EE/DRSP. Forty percent of the women with concomitant use were 35 yearsof age or older at EE/DRSP initiation compared with 29% without concomitant use (p

Original languageEnglish (US)
Pages (from-to)278-281
Number of pages4
JournalContraception
Volume76
Issue number4
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Ethinyl Estradiol
Pharmaceutical Preparations
Diuretics
Potassium
Anti-Inflammatory Agents
drospirenone
Hyperkalemia
Potassium Chloride
Progestins
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Prescriptions

Keywords

  • Concomitant treatment
  • Drospirenone
  • Hyperkalemia
  • Oral contraceptive
  • Potassium sparing
  • Progestin
  • Yasmin

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs. / McAdams Demarco, Mara Ann; Staffa, Judy A.; Dal Pan, Gerald J.

In: Contraception, Vol. 76, No. 4, 10.2007, p. 278-281.

Research output: Contribution to journalArticle

@article{8cfccdd52c614884ac4c2deb94d3426c,
title = "The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs",
abstract = "Background: Ethinyl estradiol 0.03 mg/drospirenone 3 mg (EE/DRSP) contains a progestin drospirenone with antimineralocorticoid properties that may cause potassium retention leading to hyperkalemia. We estimated the percentage of EE/DRSP users prescribed concomitant potassium-sparing drugs [nonsteroidal antiinflammatory drugs, diuretics, angiotensin-converting enzyme inhibitors (with diuretics), angiotensin II agonists (with diuretics), and potassium chloride] between January 1, 2002, and March 31, 2005. Study Design: We analyzed a population-based data set of 62,527 EE/DRSP users (Dimension Rx™, Caremark). We compared the fill date and end date for each prescription (Rx) for an interacting drug to the start and end date for each EE/DRSP episode (linked Rxs). If a day of an interacting Rx overlapped with an EE/DRSP episode, concomitant prescribing was recorded. Results: A total of 17.6{\%} of the women concomitantly used EE/DRSP and an interacting drug. Twenty-nine percent of concomitant use occurred within a month of EE/DRSP initiation. Nonsteroidal antiinflammatory drugs and diuretics were most frequently used concomitantly with EE/DRSP. Forty percent of the women with concomitant use were 35 yearsof age or older at EE/DRSP initiation compared with 29{\%} without concomitant use (p",
keywords = "Concomitant treatment, Drospirenone, Hyperkalemia, Oral contraceptive, Potassium sparing, Progestin, Yasmin",
author = "{McAdams Demarco}, {Mara Ann} and Staffa, {Judy A.} and {Dal Pan}, {Gerald J.}",
year = "2007",
month = "10",
doi = "10.1016/j.contraception.2007.06.002",
language = "English (US)",
volume = "76",
pages = "278--281",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - The concomitant prescribing of ethinyl estradiol/drospirenone and potentially interacting drugs

AU - McAdams Demarco, Mara Ann

AU - Staffa, Judy A.

AU - Dal Pan, Gerald J.

PY - 2007/10

Y1 - 2007/10

N2 - Background: Ethinyl estradiol 0.03 mg/drospirenone 3 mg (EE/DRSP) contains a progestin drospirenone with antimineralocorticoid properties that may cause potassium retention leading to hyperkalemia. We estimated the percentage of EE/DRSP users prescribed concomitant potassium-sparing drugs [nonsteroidal antiinflammatory drugs, diuretics, angiotensin-converting enzyme inhibitors (with diuretics), angiotensin II agonists (with diuretics), and potassium chloride] between January 1, 2002, and March 31, 2005. Study Design: We analyzed a population-based data set of 62,527 EE/DRSP users (Dimension Rx™, Caremark). We compared the fill date and end date for each prescription (Rx) for an interacting drug to the start and end date for each EE/DRSP episode (linked Rxs). If a day of an interacting Rx overlapped with an EE/DRSP episode, concomitant prescribing was recorded. Results: A total of 17.6% of the women concomitantly used EE/DRSP and an interacting drug. Twenty-nine percent of concomitant use occurred within a month of EE/DRSP initiation. Nonsteroidal antiinflammatory drugs and diuretics were most frequently used concomitantly with EE/DRSP. Forty percent of the women with concomitant use were 35 yearsof age or older at EE/DRSP initiation compared with 29% without concomitant use (p

AB - Background: Ethinyl estradiol 0.03 mg/drospirenone 3 mg (EE/DRSP) contains a progestin drospirenone with antimineralocorticoid properties that may cause potassium retention leading to hyperkalemia. We estimated the percentage of EE/DRSP users prescribed concomitant potassium-sparing drugs [nonsteroidal antiinflammatory drugs, diuretics, angiotensin-converting enzyme inhibitors (with diuretics), angiotensin II agonists (with diuretics), and potassium chloride] between January 1, 2002, and March 31, 2005. Study Design: We analyzed a population-based data set of 62,527 EE/DRSP users (Dimension Rx™, Caremark). We compared the fill date and end date for each prescription (Rx) for an interacting drug to the start and end date for each EE/DRSP episode (linked Rxs). If a day of an interacting Rx overlapped with an EE/DRSP episode, concomitant prescribing was recorded. Results: A total of 17.6% of the women concomitantly used EE/DRSP and an interacting drug. Twenty-nine percent of concomitant use occurred within a month of EE/DRSP initiation. Nonsteroidal antiinflammatory drugs and diuretics were most frequently used concomitantly with EE/DRSP. Forty percent of the women with concomitant use were 35 yearsof age or older at EE/DRSP initiation compared with 29% without concomitant use (p

KW - Concomitant treatment

KW - Drospirenone

KW - Hyperkalemia

KW - Oral contraceptive

KW - Potassium sparing

KW - Progestin

KW - Yasmin

UR - http://www.scopus.com/inward/record.url?scp=34548827696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548827696&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2007.06.002

DO - 10.1016/j.contraception.2007.06.002

M3 - Article

C2 - 17900437

AN - SCOPUS:34548827696

VL - 76

SP - 278

EP - 281

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -